Avamys nasal spray is for administration by the intranasal route only.
For full therapeutic benefit regular, scheduled usage is recommended. Onset of action has been observed as early as 8 hours after initial administration. However, it may take several days of treatment to achieve maximum benefit, and the patient should be informed that their symptoms will improve with continuous regular use. The duration of treatment should be restricted to the period that corresponds to allergenic exposure.
Adults and Adolescents 12 Years of Age and Older: The recommended starting dosage is 110 micrograms once daily administered as 2 sprays (27.5 micrograms/spray) in each nostril. Titrate an individual patient to the minimum effective dosage to reduce the possibility of side effects. When the maximum benefit has been achieved and symptoms have been controlled, reducing the dosage to 55 micrograms (1 spray in each nostril) once daily may be effective in maintaining control of allergic rhinitis symptoms.
Children 2 to 11 Years of Age: The recommended starting dosage in children is 55 micrograms once daily administered as 1 spray (27.5 micrograms/spray) in each nostril. Children not adequately responding to 55 micrograms may use 110 micrograms (2 sprays in each nostril) once daily. Once symptoms have been controlled, the dosage may be decreased to 55 micrograms once daily.
Children (under 2 years of age): There are no data to recommend use of AVAMYS Nasal Spray for the treatment of seasonal or perennial allergic rhinitis in children under two years of age.
Elderly: No dose adjustment is required in this population.
Renal Impairment: No dosage adjustment is required in patients with renal impairment.
Hepatic Impairment: No dose adjustment is required in patients with hepatic impairment. Caution should be exercised when dosing patients with severe hepatic impairment as patients with hepatic impairment may be more at risk of systemic adverse reactions associated with corticosteroids (see Precautions).